Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106918 | 1.00 | TP53 (0.44) | TP53SLC1A2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL4094701 | 0.87 | SLC6A9 (0.50) | SLC6A9 | |
| SCHEMBL4088265 | 0.81 | SLC6A9 (0.36) | SLC6A9 | |
| SCHEMBL4102727 | 0.81 | SLC6A9 (0.36) | SLC6A9 | |
| SCHEMBL4104611 | 0.76 | SLC6A2 (0.45) | TP53SLC1A2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL4105919 | 0.76 | SLC6A2 (0.45) | TP53SLC1A2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL4977205 | 0.76 | SLC6A2 (0.45) | TP53SLC1A2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL4103924 | 0.76 | SLC6A9 (0.49) | SLC6A9 | |
| SCHEMBL18263843 | 0.73 | SLC6A9 (0.66) | ALDH1A1SLC6A9 | |
| SCHEMBL18263721 | 0.73 | SLC6A9 (0.66) | ALDH1A1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | TP53 2149/4885SLC1A2 3477/4885KDM4E 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.